Rapid improvement in insulin binding to erythrocyte insulin receptors in non-insulin-dependent diabetes mellitus during therapy.
Insulin binding to erythrocyte receptors was studied in 36 newly diagnosed male subjects with NIDDM, treated with diet alone (Group I; n = 10) or diet + glibenclamide (Group II; n = 12) or diet + glibenclamide + metformin (Group III; n = 14). Fourteen matched non-diabetic subjects were also studied as controls. Initially, mean (+/- SD) specific insulin binding was lower in NIDDM patients than in controls (p less than 0.001), due to decreased receptor number and affinity. Control of diabetes with short-term therapy (10 +/- 2 days) resulted in significantly increased specific insulin binding in Groups II and III (p less than 0.001). A marginal increase was observed in Group I (p less than 0.01). The improved insulin binding observed in Group II and III patients after short-term therapy was maintained even after long-term therapy (9 +/- 1 months). Analysis of the insulin binding data by Scatchard plots and average affinity profiles indicated increased receptor number and affinity after short-term therapy. However, changes in affinity were reversed with long-term therapy in Groups II and III and the predominant effect appeared to be an increase in the number of binding sites.
Ramachandran
A
A
Diabetes Research Centre, Royapuram, Madras, India.
Susheela
L
L
Mohan
V
V
Kuzhali
D A
DA
Viswanathan
M
M
D000328:Adult; D001667:Binding, Competitive; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000178:diet therapy / Q000188:drug therapy; D003927:Diet, Diabetic; D004910:Erythrocyte Membrane / Q000378:metabolism*; D005500:Follow-Up Studies; D005905:Glyburide / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood*; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D011972:Receptor, Insulin / Q000378:metabolism*; D012016:Reference Values
D007328:Insulin; D008687:Metformin; D011972:Receptor, Insulin; D005905:Glyburide